6 recruiting, 2 active not recruiting, 2 completed, 1 not yet recruiting. 14 Phase 2, 5 Phase 1, 1 Phase 3.
Follow Cystoscopy: new trials by email Literature Review of Cystoscopy trials Research Report on Cystoscopy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Home-Based Outpatient Model for BCG Delivery to Reduce Undue Burden on Patients Undergoing Treatment for Non-Muscle Invasive Bladder Carcinoma BCG Solution, Best Practice, Cystoscopy - Non-Muscle Invasive Bladder Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 49 | 2027-01-15 | 2026-10-14 |
| Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Radiosensitizing Agent - Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | University of Washington | 12 | 2026-08-20 | 2026-08-25 |
| Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial Biospecimen Collection, Computed Tomography, Cystoscopy - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 111 | 2025-11-25 | 2026-11-03 |
| In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial BCG Solution, Cystoscopy, Docetaxel - Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 40 | 2025-04-21 | 2026-10-08 |
| Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer Enfortumab Vedotin, Pembrolizumab, Intensity Modulated Radiation Therapy (IMRT) - Bladder Cancer, Muscle-Invasive Bladder Carcinoma | Phase 1 / Phase 2 | Recruiting | University of California, San Francisco | 47 | 2025-03-31 | 2026-10-01 |
| Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography - Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 992 | 2024-02-02 | 2026-11-12 |
| Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance Cystoscopy, Bladder EpiCheck urine test, Xpert Bladder Cancer Monitor urine test - Non-muscle-invasive Bladder Cancer | Phase 2 | Recruiting | White River Junction Veterans Affairs Medical Center | 240 | 2023-11-17 | 2026-09-16 |
| Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial Atezolizumab, Biospecimen Collection, Computed Tomography - Bladder Carcinoma, Bladder Urothelial Carcinoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2023-10-12 | 2025-10-21 | |
| A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial Biopsy of Bladder, Biospecimen Collection, Cisplatin - Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 11 | 2021-03-17 | 2026-05-22 |
| Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 161 | 2020-03-18 | 2026-11-12 |
| Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder Durvalumab, Cystoscopy with Biopsy - Carcinoma in Situ of Bladder, Bladder Cancer | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 17 | 2017-02-16 | 2022-07-29 |
| Efficacy of Botulinum Toxin Type A in Patients With Bladder Pain Syndrome/Intersticial Cystitis and Hunners' Lesions intratrigonal injection of botulinum toxin, cystoscopy - Interstitial Cystitis | Phase 2 | Unknown | Moscow State University of Medicine and Dentistry | 60 | 2011-06-01 | 2011-09-21 |
| Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer cisplatin, gemcitabine hydrochloride, biopsy - Bladder Cancer | Phase 1 / Phase 2 | Completed | Institut du Cancer de Montpellier - Val d'Aurelle | 14 | 2005-06-01 | 2015-07-30 |
| Interstitial Cystitis H&P; ECG; Blood tests; voiding diary; Cystoscopy - Interstitial Cystitis | Phase 2 | Completed | ICOS Corporation | 150 | 2003-01-01 | 2005-06-24 |
Urinary Bladder Neoplasms (9) · Non-Muscle Invasive Bladder Neoplasms (3) · Cystitis, Interstitial (2) · Carcinoma in Situ (1) · Carcinoma, Transitional Cell (1) · Neoplasms (1) · Urinary Bladder Diseases (1)
National Cancer Institute (NCI) (5) · H. Lee Moffitt Cancer Center and Research Institute (1) · ICOS Corporation (1) · Institut du Cancer de Montpellier - Val d'Aurelle (1) · Mayo Clinic (1) · Moscow State University of Medicine and Dentistry (1) · Ohio State University Comprehensive Cancer Center (1) · University of California, San Francisco (1) · University of Washington (1) · White River Junction Veterans Affairs Medical Center (1)
United States (11) · Canada (1) · France (1) · Guam (1) · Puerto Rico (1) · Russia (1)
Cheryl T Lee, MD (1) · David Azria, MD, PhD (1) · Di Maria Jiang (1) · Florian R Schroeck, MD, MS (1) · Jingsong Zhang, M.D., Ph.D. (1) · Leslie Ballas (1) · Lyn Frumkin, M.D., Ph.D. (1) · Matthew D Galsky (1) · Michael E Woods (1) · Monika Joshi (1) · T. Martin Ma, MD, PhD (1) · Timothy D. Lyon, MD (1) · Vadim Koshkin, MD (1)
U10CA180821 (2), R37CA275916 (1), U10CA180820 (1), U10CA180888 (1), UL1TR002377 (1), UM1CA186644 (1)